University of Cincinnati

uc.edu

Total trials

319

Active

60

Phase 3

32

Total enrollment

65,362

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 25 of 25 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Escitalopram5
Duloxetine4
Exparel2
sertraline1
Bupivacain1
Sirolimus7
Conestat Alfa1
Capecitabine1
Mitomycin c1
N-acetylcysteine1
Pembrolizumab2
Gemcitabine3
Folfirinox1
Treatment Algorithm1
AM31011
Saline Placebo1
Minocycline1
Letrozole Oral2
Pendulum Glucose Control1
C-peptide1
Temozolomide1
Everolimus3
Bevacizumab2
Lumason1
chemotherapy1

Next readouts

  • 2025-06-03
  • 2025-06-13
  • 2025-06-30
  • 2025-07
  • 2025-07-30
  • 2025-07-31
  • 2025-12
  • 2026-06-29
  • 2026-06-30
  • 2026-08-01

Top conditions

  • Stroke18
  • Sarcoidosis13
  • Bipolar Disorder12
  • Traumatic Brain Injury8
  • Depression7
  • Anxiety6
  • Coronary Artery Disease5
  • Lymphangioleiomyomatosis5

Frequently asked questions about University of Cincinnati

How many clinical trials does University of Cincinnati have on ClinicalTrials.gov?
University of Cincinnati is listed as the lead sponsor on 319 clinical trials in ClinicalTrials.gov, 60 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Cincinnati's trials are in Phase 3?
32 of University of Cincinnati's trials are in Phase 3, spread across 25 active drug programs.
What therapeutic areas does University of Cincinnati focus on?
University of Cincinnati's most-studied conditions on ClinicalTrials.gov are Stroke, Sarcoidosis, Bipolar Disorder, Traumatic Brain Injury, Depression.
When are University of Cincinnati's next clinical trial readouts?
University of Cincinnati has 10 upcoming primary-completion readouts tracked here; the soonest is “Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC”, expected around 2025-06-03.